• Article published on 30 June, 2022 in Eurosurveillance: “Rapidly adapting primary care sentinel surveillance across seven countries in Europe for COVID-19 in the first half of 2020: strengths, challenges, and lessons learned”. Epiconcept´s epidemiology co-authors: D. Marques, M. Valenciano & Epiconcept´s epidemiology investigators from I-Move-Covid-19 study team: E. Kissling, A. Rose
  • WHO Article published on 2022, 16 June - Epiconcept´s epidemiology co-authors: A. Nardone, M. Valenciano "Transmission of SARS-CoV-2 in standardised first few X cases and household transmission investigations: A systematic review and meta-analysis"
  • Article published on 26 May 2022 in Eurosurveillance - Epiconcept´s epidemiology co-authors: Esther Kissling, Marta Valenciano, Angie Rose, Diogo Marques - “Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021”. 
  • Protocol. Epiconcept experts: : E. Kissling, M. Valenciano. COVID-19 vaccine effectiveness among healthcare workers in Albania (COVE-AL): protocol for a prospective cohort study and cohort baseline data. 2022, March
  • ecdc experts: S. Bacci, N. Nicolay. Epiconcept experts: : E. Kissling, A. Nardone, A. Rose, M. Valenciano. et al. Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 30 years and older, ECDC multi-country study – second update, 2022 March
  • S. Musa, E. Kissling, M. Valenciano, L. Merdrignac et al. Household transmission of SARS-CoV-2: a prospective observational study in Bosnia and Herzegovina, August–December 2020, International Journal of Infectious Diseases, 2021 November 
  • Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2, version 1.0 entrusted to the Epiconcept epidemiology team E. Kissling, A. Moren, A. Nardone, A. Rose, M. Valenciano. ecdc website, 2021 September 
  • Minal K. Patel, Isabel Bergeri, Joseph S. Bresee, Benjamin J. Cowling, Natasha S. Crowcroft, Kamal Fahmy, Siddhivinayak Hirve, Gagandeep Kang, Mark A. Katz, Claudio F. Lanata, Maïna L'Azou Jackson, Sudhir Joshi, Marc Lipsitch, Jason M. Mwenda, Francisco Nogareda, Walter A. Orenstein, Justin R. Ortiz, Richard Pebody, Stephanie J. Schrag, Peter G. Smith, Padmini Srikantiah, Lorenzo Subissi, Marta Valenciano, David W. Vaughn, Jennifer R. Verani, Annelies Wilder-Smith, Daniel R. Feikin,
    Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization, Vaccine, 2021 (in press)
  • Bergeri I, Lewis HC, Subissi L, Nardone A, Valenciano M, Cheng B, Glonti K, Williams B, Abejirinde IO, Simniceanu A, Cassini A, Grant R, Rodriguez A, Vicari A, Al Ariqi L, Azim T, Wijesinghe PR, Rajatonirina SC, Okeibunor JC, Le LV, Katz M, Vaughan A, Jorgensen P, Freidl G, Pebody R, Van Kerkhove MD. Early epidemiological investigations: World Health Organization UNITY protocols provide a standardized and timely international investigation framework during the COVID-19 pandemic. Influenza Other Respir Viruses. 2021 Oct 5. doi: 10.1111/irv.12915. Epub ahead of print. PMID: 34611986. 
  • European  Centre  for Disease Prevention  and Control.  Interim analysis of  COVID against  Severe  Acute  Respiratory Infection  due  to  laboratory confirmed SARSCoV-- 19  vaccine  effectiveness 2  among individuals aged 65  years and older, ECDC  multicountry  study.  ECDC:  Stockholm;  2021.
  • Kissling E, Hooiveld M, Sandonis Martín V, Martínez-Baz I, William N, Vilcu AM, Mazagatos C, Domegan L, de Lusignan S, Meijer A, Machado A, Brytting M, Casado I, Murray JK, Belhillil S, Larrauri A, O'Donnell J, Tsang R, de Lange M, Rodrigues AP, Riess M, Castilla J, Hamilton M, Falchi A, Pozo F, Dunford L, Cogdale J, Jansen T, Guiomar R, Enkirch T, Burgui C, Sigerson D, Blanchon T, Martínez Ochoa EM, Connell J, Ellis J, van Gageldonk-Lafeber R, Kislaya I, Rose AM, Valenciano M; I-MOVE-COVID-19 primary care study team; I-MOVE-COVID-19 primary care study team (in addition to authors above). Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021. Euro Surveill. 2021 Jul;26(29):2100670. doi: 10.2807/1560-7917.ES.2021.26.29.2100670. PMID: 34296676; PMCID: PMC8299744. 
  • World Health Organization Seroepidemiology Technical Working Group. ROSES-S: Statement from the World Health Organization on the reporting of seroepidemiologic studies for SARS-CoV-2. Influenza Other Respi Viruses. 2021; 00: 1– 8.
  • Patel MK, Bergeri I, Bresee JS, Cowling BJ, Crowcroft NS, Fahmy K, Hirve S, Kang G, Katz MA,  Lanata V, Jackson M, Joshi S, Lipsitch M, Mwenda JM, Nogareda F, Orenstein WA, Ortiz JR, Pebody R, Schrag SJ, Smith PG, Srikantiah P, Subissi L, Valenciano M, Vaughn DW, Verani JR, Wilder-Smith A, Feikin DR, Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization,Vaccine, 2021.
  • World Health Organization. (‎2021)‎. Evaluation of COVID-19 vaccine effectiveness: interim guidance, 17 March 2021. World Health Organization.
  • Cohort study to measure COVID-19 vaccine effectiveness among health workers in WHO European Region: Guidance Document. Copenhagen: WHO Regional Office for Europe; 2021.
  • Estimating COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalisations associated with laboratory-confirmed SARS-CoV-2. An evaluation using the test-negative design: guidance document. Copenhagen: WHO Regional Office for Europe; 2021.
  • Kissling E, Hooiveld M, Brytting M, Vilcu AM, de Lange M, Martínez-Baz I, Sigerson D, Enkirch T, Behillil S, Meijer A, Castilla J, William N, Carnahan AS, Falchi A, Hendriksen J, Casado Buesa I, Murray J, Enouf  V, Dijkstra F, Marques D, Valenciano M. Absence of association between 2019–20 influenza vaccination and COVID-19: results of the European I-MOVE-COVID-19 primary care project, March–August 2020. Authorea. January 03, 2021. DOI: 10.22541/au.160968257.71855237/v1 



Papillomavirus Humain

  • Measuring the effectiveness and the impact of HPV vaccination, Synthesis Document. Prepared for SPMSD by Halm A, Valenciano M, Moren A. Version 5. Jul 2010.
  • Evaluating of the impact of Human Papillomavirus vaccination, Generic protocol for before-after comparison studies. Prepared for SPMSD by Halm A, Valenciano M, Moren A. Jun 2010.
  • Evaluating the effectiveness of the Human Papillomavirus vaccine, Draft Generic Protocol for HPV vaccine effectiveness studies. Prepared for SPMSD by Savulescu C, Halm A, Valenciano M, Moren A. Jan 2011.
  • Evaluating the effectiveness of quadrivalent vaccine against four type Human Papilloma Virus’ oral and oro-pharyngeal infections in French female university students. Prepared for SPMSD by Savulescu C, Valenciano M, Moren A. Oct 2010.


Infections invasives à pneumocoque

  • Epiconcept's epidemiologists co-authors : C. Savulescu, G. Hanquet and SpIDnet group. Article available online since 28 May 2022 : "Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study".!
  • Deloria Knoll, M.; Bennett, J.C.; Garcia Quesada, M.; Kagucia, E.W.; Peterson, M.E.; Feikin, D.R.; Cohen, A.L.; Hetrich, M.K.; Yang, Y.; Sinkevitch, J.N.; et al. Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project. Microorganisms 2021, 9, 742. 
  • European Centre for Disease Prevention and Control. Generic protocol on enhanced surveillance for invasive pneumococcal disease at the EU/EEA level. Stockholm: ECDC; 2018. Authors: Savulescu C, Hanquet G, Valenciano M, Moren A – Epiconcept
  • Hanquet G, Krizova P, Valentiner-Branth P, Ladhani SN, Nuorti JK, Lepoutre A, Mereckiene J, Knol M, Winje BA, Ciruela P, Ordobas M, Guevara M, McDonald E, Morfeldt E, Kozakova J, Slotved HC, Fry NK, Rinta-Kokko H, Varon E, Corcoran M, van der Ende A, Vestrheim DF, Munoz-Almagro C, Latasa P, Castilla J, Smith A, Henriques-Normark B, Whittaker R, Pastore Celentano L, Savulescu C. and SpIDnet/I-MOVE+ pneumo group. Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of ten European countries. Implications for adult vaccination. Accepted for publication in Thorax
  • Savulescu C, Krizova P, Lepoutre A, Mereckiene J, Vestrheim DF, Ciruela P, Ordobas M, Guevara M, McDonald E, Morfeldt E, Kozakova J, Varon E, Cotter S, Winje BA, Munoz-Almagro C, Garcia L, Castilla J, Smith A, Henriques-Normark B, Celentano LP, Hanquet G; SpIDnet group. Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study. Lancet Respir Med. 2017 Mar 27. pii: S2213-2600(17)30110-8. doi: 10.1016/S2213-2600(17)30110-8.

Maladie à virus Ebola

  • Exposure Patterns Driving Ebola Transmission in West Africa: A Retrospective Observational Study. PLoS Med. 2016 Nov 15;13(11):e1002170. doi: 10.1371/journal.pmed.1002170. eCollection 2016 Nov.
  • Rico A, Brody D, Coronado F, Rondy M, Fiebig L, Carcelen A, Deyde VM, Mesfin S, Retzer KD, Bilivogui P, Keita S, Dahl BA. Epidemiology of Epidemic Ebola Virus Disease in Conakry and Surrounding Prefectures, Guinea, 2014-2015. Emerg Infect Dis. 2016 Feb;22(2):178-83. doi: 10.3201/eid2202.151304.
  • Dixon MG, Taylor MM, Dee J, Hakim A, Cantey P, Lim T, Bah H, Camara SM, Ndongmo CB, Togba M, Touré LY, Bilivogui P, Sylla M, Kinzer M, Coronado F, Tongren JE, Swaminathan M, Mandigny L, Diallo B, Seyler T, Rondy M, Rodier G, Perea WA, Dahl B. Contact Tracing Activities during the Ebola Virus Disease Epidemic in Kindia and Faranah, Guinea, 2014. Emerg Infect Dis. 2015 Nov;21(11):2022-8. doi: 10.3201//eid2111.150684.


  • Rondy M, Issifou D, Ibrahim AS, Maman Z, Kadade G, Omou H, Fati S, Kissling E, Meyer S, Ronveaux O. Vaccine Effectiveness of Polysaccharide Vaccines Against Clinical Meningitis - Niamey, Niger, June 2015. PLoS Curr. 2016 Apr 18;8. pii: ecurrents.outbreaks.5d6e9c1d071a2088109c242771b68886. doi: 10.1371/currents.outbreaks.5d6e9c1d071a2088109c242771b68886.



Urgences complexes - Surveillance


  • A. Nardone with Public Health England and University College London Teams: PrEP use and unmet PrEP-need among men who have sex with men in London prior to the implementation of a national PrEP programme, a cross-sectional study from June to August 2019 - June 2022
  • Burckhardt F, Kissling E. Training for Foodborne Outbreak Investigations by Using Structured Learning Experience. Emerg Infect Dis. 2020;26(1):162-164. 
  • Halm A, Seyler T, Mohamed S, Ali Mbaé SB, Randrianarivo-Solofoniaina AE, Ratsitorahina M, Nundlall R, Aboobakar S, Bibi J, Filleul L, Piola P, Razafimandimby H, Rasamoelina H, Valenciano M, Moren A, Cardinale E, Lepec R, Flachet L. Four years into the Indian ocean field epidemiology training programme. Pan Afr Med J. 2017 Apr 4;26:195. doi: 10.11604/pamj.2017.26.195.10358
  • Krause G, Stefanoff P, Moren A. Applied epidemiology training in Europe: quite a success - but more to be done. Euro Surveill. 2009 Oct 29;14(43).
  • Hanquet G, Valenciano M, Simondon F, Moren A. Vaccine effects and impact of vaccination programmes in post-licensure studies. Vaccine 2013;31: 5434-42
  • Le Polain de Waroux O, Maguire H, Moren A. The case-cohort design in outbreak investigations. Euro Surveill. 2012 Jun 21;17(25). pii: 20202.
  • Checklist for reviewing protocols of observational epidemiological studies. Preparé pour SPMSD par Halm A, Valenciano M, Moren A. Version 5.2. Sep 2012.